Cipla approves FY26 results and recommends INR 13 final dividend

Cipla Ltd ( (IN:CIPLA) ) has issued an update.

Cipla Ltd, a major Indian pharmaceutical manufacturer of generic and branded medicines, reported its audited standalone and consolidated financial results for the quarter and full year ended 31 March 2026. The results, along with an unmodified auditor’s report and a confirmation from the Global Chief Financial Officer, have been approved by the board and made available in the investor section of the company’s website.

The board also recommended a final dividend of INR 13 per equity share for FY 2026, with a record date of 5 June 2026 and payment to follow within 30 days of shareholder approval at the Annual General Meeting. The move underscores Cipla’s continued focus on shareholder returns and regulatory compliance as it maintains transparent financial reporting across multiple stock exchanges in India and Luxembourg.

More about Cipla Ltd

Cipla Ltd is a leading Indian pharmaceutical company headquartered in Mumbai, operating in the global generics and branded formulations market. The company focuses on a wide range of therapies and healthcare products, supplying medicines to domestic and international markets through its regulated manufacturing and distribution network.

Average Trading Volume: 104,364

Technical Sentiment Signal: Hold

Current Market Cap: 1043.7B INR

See more data about CIPLA stock on TipRanks’ Stock Analysis page.